Acutely ill asthmatic patients treated in the usual fashion in an emergency room setting and discharged within six hours were studied to determine whether therapy with a single injection of a repository corticosteroid (methylprednisolone sodium acetate) could be as effective as a tapering course of oral corticosteroids in decreasing asthma symptomatology and relapse within seven days. Seventeen patients (18 episodes of asthma) formed the study population. Eight episodes occurred in patients who received depot methylprednisolone (group 1) and ten episodes in patients who received oral corticosteroid treatment (group 2). All patients Bronchial asthma is a common disorder, accounting for hundreds of thousands of emergency room (ER) visits yearly. The Subjects were treated for acute asthma in standard fashion. All received inhaled metaproterenol via mininebulizer, while three patients in each group also received subcutaneous epinephrine (0.3 ml) at 20-min intervals (up to three doses, at the discretion of the ER physician). All patients except one received intravenous aminophylline (an initial bolus of 5.6 mg/kg over 20 min if not previously on aminophylline, or one-half that loading dose if on aminophylline therapy; this was followed by a maintenance drip between 0.3 and 0.7 mg/kg/hr, depending on the medical history). Some patients received nasal oxygen at 2 to 3 L/min, also at the discretion of the treating physician.
Bronchial asthma is a common disorder, accounting for hundreds of thousands of emergency room (ER) visits yearly. The relapse rate in asthmatic patients treated initially in an ER setting (but not admitted to the hospital) can be as high as 25 percent within ten days.' Any effective means of decreasing this relapse rate would be important, both for the reduction of asthma-related morbidity and potential mortality, as well as the associated economic loss.
Corticosteroid therapy is useful in managing the acutely ill asthmatic patient in the hospital.25 In a previous study, we demonstrated that a tapering course of oral methylprednisolone given to nonhospitalized acute asthmatic patients was effective in decreasing both the rate of relapse and the recurrence of respiratory symptoms.6 Since compliance with prescribed medication is a well-known problem, we endeavored to determine whether therapy with a single intramuscular injection of a repository corticosteroid prior to discharge could be as effective as oral corticosteroid therapy administered in the outpatient setting.
MATERIALS AND METHODS
Twenty-two patients with acute asthma presenting to the Temple University Hospital emergency room were initially enrolled in the study, although follow-up was available for only 18. All patients met the American Thoracic Society criteria for asthma. 7 Patients between the ages of 15 and 55 years were considered for participation in Subjects were treated for acute asthma in standard fashion. All received inhaled metaproterenol via mininebulizer, while three patients in each group also received subcutaneous epinephrine (0.3 ml) at 20-min intervals (up to three doses, at the discretion of the ER physician). All patients except one received intravenous aminophylline (an initial bolus of 5.6 mg/kg over 20 min if not previously on aminophylline, or one-half that loading dose if on aminophylline therapy; this was followed by a maintenance drip between 0.3 and 0.7 mg/kg/hr, depending on the medical history). Some patients received nasal oxygen at 2 to 3 L/min, also at the discretion of the treating physician.
There were frequent reevaluations of clinical status, and patients were discharged when deemed appropriate after clinical evaluation. Patients whose clinical status indicated that discharge was inappropriate after six hours of ER treatment (continued significant wheezing or dyspnea) were admitted to the hospital and dropped from participation in the study.
Once a medical decision was made to discharge an eligible patient from the ER (within six hours of arrival), informed consent was obtained and the patient was enrolled in the study. All subjects were given an intravenous injection of 4 mg/kg of methylprednisolone sodium succinate, then randomized in double-blind fashion to receive either an intramuscular injection of methylprednisolone sodium acetate (80 mg) followed by seven days of oral placebo therapy, or an intramuisctular injection of placebo followed by oral methylprednisolone therapy, starting at 32 mg twice a day, and tapering to zero over eight days (64 mg days 1 and 2, 32 mg day 3, 24 mg day 4, 16 mg day 5, 12 mg day 6 and 4 mg day 7). Oral placebo and oral methylprednisolone were indistinguishable, and the dosage and tapering scheduile were the same as in our previous study.6
Subjects were all placed on a standard regimen of oral anhydrous long-acting theophylline at a dose of 300 mg twice a day. They were told to uise inhaled beta agonists as needed. Therapy with asthma medications other than the above was discontinuied.
Subjects were evaluiated and scored by the 
RESULTS
The study consisted of 18 episodes of acute asthma. Sixteen patients presented to the ER on one occasion each, and one patient had two acute asthmatic episodes during the study period. Eight episodes occurred in patients receiving treatment with intramuscular methylprednisolone sodium acetate (group 1), and ten in patients receiving oral methylprednisolone (group 2).
Characteristics of the two groups were not significantly different on entry into the study with regard to sex, age, height or weight (Table 1 ). In addition, there was no significant difference in Fischl predictor index or peak expiratory flow rate between the two groups, either on admission to or discharge from the ER (Table  2) , nor were there any observed differences in the use of epinephrine or intravenous aminophylline in the ER.
Follow-up was obtained by return visit in seven of eight patients in group 1, and in nine of ten patients in group 2. One patient in each group was contacted for follow-up information by telephone. All patients in both groups improved following ER treatment. Peak expiratory flow rate was less in group 2 than in group 1 on follow-up evaluation, although the difference did Adverse effects from corticosteroid therapy were rare. One patient in each group reported gastrointestinal distress. Two patients in group 1 (20 percent) reported pain at the injection site, while pain was not reported at all in group 2. No swelling or redness at the injection site was reported in either group.
A greater number of patients in group 2 utilized inhaled beta agonist therapy following discharge from the ER (group 1, three of eight [37.5 percent] vs group 2, six of ten [60 percent]).
DISCUSSION
Corticosteroids are widely used in the treatment of severe asthma, with several recent studies demonstrating their efficacy in hospitalized patients,235 and another study showing decreased need for hospitalization in acutely ill asthmatic adults given early intravenous corticosteroid treatment in the ER. 10 Only a single study has examined the effect ofcorticosteroid therapy on actutely ill asthmatic patients presenting to an ER but not admitted to the hospital.6 In that study, asthmatic patients treated in the ER with standard bronchodilators and discharged on a schedule oftapering oral corticosteroid therapy had a 5.9 percent relapse rate and a 15.6 percent respiratory symptom Either symptom 0 9 <.01
Oral vs Repository Corticosteroid Therapy (Hoffman, Fiel) rate at seven to ten days post-discharge. A similar group discharged with oral placebo therapy had a 21 percent relapse rate and a 36.4 percent respiratory symptom rate during the same interval. Knowing that compliance with oral medication can be a serious problem," we sought to determine whether a single intramuscular injection of a longacting corticosteroid was as effective as the tapering oral schedule in the management of the acute asthmatic patient. In addition, we felt that the more uniform blood levels maintained by an intramuscular injection of methylprednisolone sodium acetate might also enhance corticosteroid efficacy. A similar approach has demonstrated that intramuscular triamcinolone acetonide can be an effective and safe option in the chronic management of the severe corticosteroid-dependent asthmatic patient. '2 Methylprednisolone sodium acetate (40 mg) given intramuscularly reaches a peak serum concentration of 148 ± 86 F.g/100 ml in 7.3 ±1.04 h in normal volunteers.'3 The apparent half-life is 69.3 h, reflecting the prolonged release of this dosage form. 13 Our study has demonstrated that therapy with intramuscular methylprednisolone sodium acetate, following the intravenous administration of methylprednisolone sodium succinate, given to asthmatic patients not ill enough to require hospitalization, is effective in preventing relapse and reappearance of respiratory symptoms within seven days following treatment. Even though the patient population was small, a statistically significant difference in symptomatology between the two groups was demonstrated at the time of follow-up.
The percentage of patients either relapsing (20 percent) or experiencing respiratory symptoms (90 percent) in the oral corticosteroid treated group was much higher than that in an identically treated group in our earlier study.6 Reasons for this difference can only be speculative, but may be related both to noncompliance with some aspect of therapy and to the small size of the group.
Therapy with intramuscular methylprednisolone sodium acetate appears to be safe and well tolerated. Two of eight patients (25 percent) experienced minor pain at the injection site, but this was of short duration and not a serious medical problem.
The fact that there was a zero percent rate of both relapse and symptoms in the depot-treated group is interesting and of potential importance. Further studies utilizing larger numbers ofpatients will be required to confirm this finding. However, it does appear that depot corticosteroids may be a useful alternative to oral corticosteroids in management of the acutely ill asthmatic patient, both from the standpoint of improved patient care as well as patient compliance.
